Henry F Mcfarland

US Patent:

7258859, Aug 21, 2007

Filed:

Jun 27, 2003

Appl. No.:

10/607598

Inventors:

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 38/21

US Classification:

4241841, 424 856, 4241431

Abstract:

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

US Patent:

7575742, Aug 18, 2009

Filed:

Nov 27, 2002

Appl. No.:

10/519311

Inventors:

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 38/21
A61K 39/395
C07K 14/00
C07K 16/00

US Classification:

424 854, 4241431, 530351, 53038822

Abstract:

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

US Patent:

8293800, Oct 23, 2012

Filed:

Apr 28, 2010

Appl. No.:

12/768930

Inventors:

Thomas Meier - Basel, CH
Bibiana Bielekova - Kensington MD, US
Henry F. McFarland - Gaithersburg MD, US

Assignee:

Santhera Pharmaceuticals (Schweiz) AG - Liestal
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 31/12

US Classification:

514689, 514678

Abstract:

The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.

US Patent:

8298525, Oct 30, 2012

Filed:

Mar 10, 2009

Appl. No.:

12/401543

Inventors:

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 38/21
A61K 39/395
A61K 38/20
C07K 14/55
C07K 16/28

US Classification:

424 854, 4241431, 530351, 5303882

Abstract:

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

US Patent:

8454965, Jun 4, 2013

Filed:

Jul 13, 2007

Appl. No.:

11/827876

Inventors:

Roland Martin - Hamburg, DE
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US

Assignee:

The United States of America as represented by The Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/395
C07K 16/00

US Classification:

4241841, 4241431, 5303881, 53038822

Abstract:

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

US Patent:

8636997, Jan 28, 2014

Filed:

Sep 12, 2012

Appl. No.:

13/612763

Inventors:

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 38/21
A61K 39/395
C07K 14/565
C07K 16/28

US Classification:

424 856, 4241441, 530351, 53038822

Abstract:

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

US Patent:

20040180808, Sep 16, 2004

Filed:

May 2, 1995

Appl. No.:

08/431644

Inventors:

STEVEN H. NYE - MEQUON WI, US
MICHAEL J. LENARDO - POTOMAC MD, US
HENRY F. MCFARLAND - GAITHERSBURG MD, US
LOUIS A. MATIS - SOUTHPORT CT, US
EILEEN E. MUELLER - EAST HAVEN CT, US
JOHN P. MUELLER - EAST HAVEN CT, US
CLARA M. PELFREY - GAITHERSBURG MD, US
STEPHEN P. SQUINTO - BETHANY CT, US
JAMES A. WILKINS - WOODBRIDGE CT, US

International Classification:

A61K038/17
C07H021/04
C07K014/435

US Classification:

514/002000, 536/023500, 530/350000, 530/324000, 530/325000, 530/326000, 530/327000, 514/012000

Abstract:

Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.

US Patent:

20070237717, Oct 11, 2007

Filed:

Apr 5, 2004

Appl. No.:

11/578207

Inventors:

Roland Martin - Bethesda MD, US
Louis Staudt - Silver Spring MD, US
Henry McFarland - Gaithersburg MD, US
Claus-Steffen Sturzebecher - Berlin, DE

International Classification:

A61K 49/00
C12Q 1/68

US Classification:

424009100, 435006000

Abstract:

A variety of therapies are used to treat autoimmune diseases such as multiple sclerosis. However, there is no single therapy that can be used to treat all subjects. Thus, a method is provided to determine if a subject with an autoimmune disease, such as multiple sclerosis, will respond to a therapeutic protocol. The method includes analyzing the expression of genes expressed by the immune system. Although the expression of a single gene can be assessed, such as interleukin-8, the methods include evaluating the expression profile of a subject using an array (such as a microarray) to determine if the subject is appropriately responding to the therapeutic protocol.